Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 5/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988485 | 0.85 | EGFR (0.38) | CYP2D6HIF1A | |
| SCHEMBL2987301 | 0.85 | ALOX5 (0.46) | TSHR | |
| SCHEMBL2978643 | 0.84 | KDM4E (0.33) | HTR2A | |
| SCHEMBL2982521 | 0.80 | HTR1A (0.44) | HTR1AHSPA5TAAR1MPOAKR1B1 | |
| SCHEMBL2982522 | 0.80 | HTR1A (0.44) | HTR1AHSPA5TAAR1MPOAKR1B1 | |
| SCHEMBL27796477 | 0.78 | KDM4E (0.46) | TAAR1SLC6A4TSHR | |
| SCHEMBL8142434 | 0.67 | TAAR1 (0.50) | HTR1AHSPA5TAAR1MPOAKR1B1 | |
| SCHEMBL10962774 | 0.67 | HTR1A (0.70) | HTR1AHSPA5TAAR1MPOAKR1B1 | |
| SCHEMBL36797 | 0.66 | HTR2A (0.65) | HTR1AHSPA5TAAR1MPOHTR2A | |
| SCHEMBL1222973 | 0.66 | TAAR1 (0.71) | HTR1AHSPA5TAAR1MPOAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | TYR, MMP17, MMP1 | HTR1A 1100/4885HSPA5 4410/4885TAAR1 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.